Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Acorda Therapeutics Inc ACORQ

Healthcare Biotechnology
Acorda Therapeutics, Inc. is a biopharmaceutical company focused on developing therapies that restore function and improve the lives of people with neurological disorders. The Company markets Inbrija (levodopa inhalation powder), which is approved in the United States for intermittent treatment of OFF episodes, also known as OFF periods, in people with Parkinson’s disease treated with carbidopa... see more

Recent & Breaking News (OTCPK:ACORQ)

Acorda Therapeutics to Present at the 28th Annual Piper Jaffray Healthcare Conference

Business Wire November 22, 2016

Mid-Day Market Update: Headwaters Surges On Acquisition News; Cubic Shares Slide

Benzinga.com  November 21, 2016

Mid-Morning Market Update: Markets Open Higher; Symantec To Acquire Lifelock

Benzinga.com  November 21, 2016

15 Stocks Moving In Monday's Pre-Market Session

Benzinga.com  November 21, 2016

Acorda to Discontinue Development of Dalfampridine for Treatment of Post-Stroke Walking Difficulties

Business Wire November 21, 2016

Acorda Therapeutics to Present at the Stifel 2016 Healthcare Conference

Business Wire November 9, 2016

Acorda Provides Financial and Pipeline Update for Third Quarter 2016

Business Wire October 27, 2016

Acorda to Host Conference Call to Discuss Third Quarter 2016 on October 27, 2016

Business Wire October 17, 2016

Data from Clinical and Preclinical Trials of CVT-301 for Treatment of OFF Periods in Parkinson’s Disease Published in Science Translational Medicine

Business Wire October 13, 2016

Acorda Named One of the Best Workplaces by Fortune Magazine and Great Place to Work

Business Wire October 12, 2016

Acorda Announces Departure of Michael Rogers

Business Wire October 4, 2016

Stocks Hitting 52-Week Lows

Benzinga.com  September 29, 2016

Monday Market Wrap: Stocks Fall Nearly 1% To Start Week

Benzinga.com  September 26, 2016

Mid-Afternoon Market Update: Dow Falls 150 Points; Himax Technologies Shares Slide After Nomura Downgrade

Benzinga.com  September 26, 2016

Mid-Day Market Update: Crude Oil Up 3.3%; Chemtura Shares Surge Following Acquisition News

Benzinga.com  September 26, 2016

Mid-Morning Market Update: Markets Open Lower; Cal-Maine Posts Wider-Than-Expected Loss

Benzinga.com  September 26, 2016

Acorda Launches “The Many Faces of OFF” Facebook Page to Support Parkinson’s Community

Business Wire September 15, 2016

Acorda Provides Financial and Pipeline Update for Second Quarter 2016

Business Wire July 28, 2016

Acorda to Host Conference Call to Discuss Second Quarter 2016 on July 28, 2016

Business Wire July 7, 2016

Acorda Appoints Burkhard Blank, M.D., as Chief Medical Officer (CMO)

Business Wire July 1, 2016